The aim is to identify and optimize YTB53 as a potential therapy for acute myeloid leukemia (AML).
Discovery of YTB53 through marine sources.
Evaluation of its anti-AML properties and kinase activity.
Plans for medicinal chemistry optimization to enhance pharmacokinetics.
YTB53 exhibits promising anti-AML activity.
Demonstrates multi-kinase activity relevant for AML treatment.
Abstract
as a promising multimechanistic lead for AML therapy, warranting further medicinal chemistry optimization to improve its pharmacokinetic properties and advance its development potential.